Aparna Parikh, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Abbvie
    Topic:
    Advisor/consultant
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Roche
    Topic:
    on DSMC for a study
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    PureTech
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    PMV Pharmaceuticals
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Plexxicon
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Takeda
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    BMS
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Mirati
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Novartis
    Date added:
    04/14/2022
    Date updated:
    04/17/2023
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Genentech
    Date added:
    04/14/2022
    Date updated:
    04/17/2023

Pages

Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology